Molecular and cytogenetic abnormalities in acute myeloid leukaemia and myelodysplastic syndromes.
With the use of molecular techniques it is now possible to define even subtle chromosomal abnormalities and the fusion products resulting from translocations. Defined clinical correlations can now be made and prognostic implications are already found. For instance, patients with AML carrying t(8;21), t(15;17) or inv(16) have a better prognosis for long-term survival. This is also illustrated by Figure 1, which shows data of the Dutch HOVON AML study. The definition of patients with a bad or good prognosis has already resulted in the adjustment of treatment protocols. In the near future, with the use of more defined molecular techniques, we might be able to characterize the chromosomal abnormality of each patient, to individualize his treatment and to recognize very early relapses.